Foghorn Therapeutics Inc
Foghorn Therapeutics Inc (FHTX) Covered Calls
Read more
Running FHTX covered calls helps you generate income from Foghorn Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best FHTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If FHTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling FHTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given FHTX covered call is worth writing.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.
No illustrative rows to display.
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank23.02% Low
- Market cap (M$)124
- 52 weeks high-72.80%
- 52 weeks low15.64%
- Analyst recommendationBuy
2.00 - Target price$5.00
141.55% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E66.56
- Future P/E—
- EPS (ttm)0.03
- EPS growth next 5 years7.74%
As of Nov 13, 2026